Due to the paramount role of androgen receptor (AR) signaling in prostate cancer cell growth and survival in the regulation of cell growth and survival [2–4], androgen deprivation therapy (ADT), which inhibits AR signaling, has been the standard treatment for early-stage and metastatic prostate cancer until recently [5, 6]. The gene discussed is AR; the disease is prostate carcinoma.